Please login to the form below
emicizumab
This page shows the latest emicizumab news and features for those working in and with pharma, biotech and healthcare.
Genentech announces positive phase 3 trial results for haemophilia A
Genentech has announced positive results from a phase 3 trial, showing that Hemlibra (emicizumab-kxwh) continued to demonstrate ‘clinically meaningful’ bleed control in patients with moderate or mild haemophilia A, without
Latest news
-
Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
Finally, interim data from the phase 3 HAVEN 6 study will be presented at the ASH meeting showing that Hemlibra (emicizumab) had a favourable safety and efficacy profile for people with
-
Roche cites COVID-19 and biosimilars in Q2 decline
Although sales of Roche's newer drugs climbed by 37%, including haemophilia A treatment Hemlibra (emicizumab), multiple sclerosis therapy Ocrevus (ocrelizumab) and PD-1 inhibitor Tecentriq (atezolizumab), this was unable to
-
Novo Nordisk hits pause on rival to Hemlibra for haemophilia
Concizumab is a potential rival to Roche’s blockbuster Hemlibra (emicizumab), the first non-clotting factor therapy for haemophilia A to reach the market, although it targets a different part of
-
Roche posts minor sales miss in Q4 as biosimilar pressure grows
Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely Perjeta (pertuzumab) for HER2-positive breast cancer, Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy Hemlibra (emicizumab) and
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
Regulators had been scrutinising the deal because Roche’s antibody drug Hemlibra (emicizumab) has been growing at an impressive rate since its launch last year, and is firmly on course to
More from news
Approximately 5 fully matching, plus 35 partially matching documents found.
Latest from PMHub
-
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Other recently approved products, emicizumab for haemophilia A and asfotase alfa for hypophosphatasia, also saw costs increase by more than 200 per cent in 2020/21.
-
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
These include the cystic fibrosis treatment ivacaftor (up 225.5 per cent), emicizumab for haemophilia patients (up 247.3 per cent) and asfotase alfa for the genetic disorder hypophosphatasia (up
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- How an AI algorithm might save your life
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Tuberculosis – why it remains a major global public health challenge
- Whitepaper: Closing the gap with compelling healthcare communications
No results were found
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
